News archive
Showing 639 results
June 2020
-
Media ReleaseNovartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
Media ReleaseNovartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritisFDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
-
Media ReleaseNovartis ILARIS® (canakinumab) receives FDA approval for new indication to treat Adult-Onset Still’s Disease (AOSD)FDA granted an indication for active Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD, a serious and rare inflammatory disorder with high unmet medical need1,2…
-
Media ReleaseNovartis manufactures and donates 27,000 units of hand sanitizer to New York StateNovartis donates 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency Donation builds on Novartis efforts in the US for communities impacted by…
-
Media ReleaseU.S. FDA approves updated Novartis BEOVU® label, to include additional safety informationNovartis worked with U.S. Food and Drug Administration (FDA) to update BEOVU (brolucizumab-dbll) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1…
May 2020
-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgeryMore than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years(1) Study conclusions are drawn from the largest dataset and…
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)A post hoc analysis of Phase III ASCLEPIOS I and II trials showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months…
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive diseaseNew MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life compared…
-
Media ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14